<DOC>
	<DOCNO>NCT03067363</DOCNO>
	<brief_summary>This first human study MOR107 . It 2 part , single centre , double-blind , randomise , placebo-controlled study healthy male subject . Part 1 single ascend dose study , Part 2 parallel group , dose range find study healthy male subject low sodium diet .</brief_summary>
	<brief_title>First Human Single Ascending Dose Study MOR107</brief_title>
	<detailed_description>MOR107 angiotensin 2 receptor ( AT2R ) agonist potential treat wide range disease activation protective arm renin-angiotensin system . In study MOR107 administer human first time . The study enroll healthy male subject split two sequential part , single centre , double-blind , randomise , placebo-controlled design . Part 1 evaluate safety , tolerability pharmacokinetics ( PK ) single ascend dos MOR107 . Part 2 evaluate pharmacodynamics , safety , tolerability PK three different dos MOR107 healthy male subject feed low sodium diet order increase AT2R expression .</detailed_description>
	<criteria>Key 1 . Healthy male 2 . Age 18 45 year age 3 . Body mass index 18.0 32.0 kg/m2 4 . For Part 2 , subject must least 25 % reduction 24 hour urinary sodium excretion Day 2 compare admission Key 1 . Subjects receive IMP clinical research study within previous three month 2 . Regular alcohol consumption &gt; 21 unit per week ( 1 unit = Â½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) 3 . Current smoker smoke within last 12 month . A breath carbon monoxide read great 10 ppm screening/admission 4 . Current smoker ecigarettes nicotine replacement product smoke product within last 12 month 5 . Clinically significant abnormal biochemistry , haematology urinalysis judge investigator 6 . Positive drug abuse test result 7 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result 8 . History psychiatric disorder , cardiovascular , renal , hepatic , chronic respiratory gastrointestinal disease judge investigator 9 . Serious adverse reaction serious hypersensitivity drug formulation excipients</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>